Target intelligence / Profile preview

Fibrin matrix

Molecular classification
Other (biological matrix; not a receptor, enzyme, ion channel, transporter, or transcription factor)
01

Overview

The fibrin matrix is a network-like scaffold formed by polymerization of fibrin monomers, which are derived from fibrinogen after enzymatic cleavage by thrombin. This matrix is essential for stabilizing blood clots, facilitating wound healing, and serving as a scaffold for cell growth in tissue engineering. Its viscoelastic properties depend on covalent cross-linking by factor XIIIa, and the matrix can be remodeled by cellular and proteolytic activity (mainly by plasmin)[1][3][6][5][7]. Its mechanical and biochemical environment supports cell adhesion, migration, and proliferation, and its regulated breakdown is crucial for homeostasis and tissue repair[2][4][6]. Fibrin matrix abnormalities are implicated in various diseases, especially those related to thrombosis, cardiovascular pathology, and wound healing defects[1][6]. The term "Fibrin matrix" captures a biological scaffold, not a distinct protein, receptor, or enzyme; therefore, it should not be considered a classical molecular therapeutic target but the context for drug action and biomaterial engineering[1][2][3][6].

Other names
Fibrin clotBlood clot scaffoldFibrin polymerFibrin network
02

Mechanism of action

Fibrinolytics: Activate plasminogen to plasmin, which degrades the fibrin matrix; Anticoagulants: Prevent thrombin formation, inhibiting conversion of fibrinogen to fibrin; Antiplasmins: Inhibit plasmin, preventing fibrin degradation.

03

Biological functions

Hemostasis and formation of blood clotsWound healing scaffoldExtracellular matrix support for cell growth in tissue engineeringMediator of fibrinolysis
04

Disease associations

ThrombosisCardiovascular diseaseWound healing impairmentInflammation
05

Safety considerations

Risk of bleeding: Excessive fibrin breakdown can cause bleedingThrombosis: Excessive or abnormal fibrin matrix formation leads to pathologic clotsImmunogenicity: Potential risk in tissue engineering from non-autologous materialsDegradation resistance: Abnormal cross-linking can make the matrix overly resistant to breakdown
06

Interacting drugs

Fibrinolytic agents (e.g., tissue plasminogen activator (tPA))

3 more in the full profile.

07

Biomarkers

D-dimer (a fibrin degradation product used to monitor clot breakdown and diagnose thrombotic disorders)

Beyond the preview

Go deeper on Fibrin matrix.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fibrin matrix.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call